What "multipotent" means here
Mesenchymal stem cells, or MSCs, are multipotent, meaning a single MSC can develop into a limited set of related cell types, rather than into any cell type in the body. Specifically, MSCs are studied for their capacity to form bone, cartilage, and fat lineages. That's narrower than the popular idea of a "stem cell" that can become anything, and the distinction matters when evaluating any claim made about them.
Where MSCs are typically found, and why cord blood isn't one of them
MSCs are most commonly sourced from bone marrow, adipose (fat) tissue, and umbilical cord tissue, not cord blood itself. Cord blood is rich in a different cell type, hematopoietic stem cells (HSCs), which is why cord blood and cord tissue are banked and processed separately even though they're collected at the same time, at birth. If you're banking both, you're banking two related but distinct cell populations, not one cell type in two forms. Our Gold package banks cord blood only; Diamond, Platinum, and Royal all add cord tissue, so MSC banking specifically starts at Diamond.
Why they're studied beyond bone and cartilage
Separate from their differentiation capacity, MSCs are studied for immunomodulatory signaling, meaning they can influence the behavior of nearby immune cells. This is a distinct area of research from their use in forming tissue, and it's one of the reasons MSCs appear so frequently in regenerative medicine literature: they're being investigated for two different kinds of biological activity, not just one.
What "studied for" doesn't mean
Being studied for a capacity is not the same as that capacity being an established, guaranteed clinical outcome. Research into MSC applications spans a wide range of maturity, from well-characterized laboratory findings to early-stage clinical investigation. Any claim that treats MSC banking as a guaranteed future treatment is overstating the current state of the evidence, and this is exactly the gap where cell-banking marketing tends to overreach. Both the International Society for Stem Cell Research (ISSCR) and the FDA have published public warnings specifically about unproven stem-cell and exosome marketing claims, aimed at helping people evaluate this kind of offer critically rather than take "studied for" as a synonym for "proven to work."
Why collecting at birth matters
The rationale for banking cord tissue MSCs specifically at birth rests on the general premise that cell populations change with age and environmental exposure over a lifetime, so cells collected at birth are captured before that accumulated exposure occurs. This is a reasonable premise, but it is a premise about potential future usefulness, it should be presented as reasoning, not as a settled proven outcome about how any specific future treatment will perform.
Further reading: Jiang W, Xu J, "Immune modulation by mesenchymal stem cells," Cell Proliferation 53(1):e12712 (2020); Wang Y et al., "Mesenchymal stem cells and immunomodulation: current status and future prospects," Cell Death & Disease 7, e2062 (2016); ISSCR Patient Handbook, isscr.org/patients; FDA public safety alert on unapproved stem cell and exosome products, fda.gov.
This article is general-education content describing what mesenchymal stem cells are. It is not a citation and does not substitute for peer-reviewed sources, which are required before any specific MSC-related claim is published as fact elsewhere on this site.